NEC baby formula lawsuit: premature infant injury claims

Understanding necrotizing enterocolitis and the NEC baby formula lawsuit

Necrotizing enterocolitis (NEC) is one of the most devastating gastrointestinal emergencies affecting premature infants. This condition causes inflammation, bacterial invasion, and necrosis of the intestinal tissue, often leading to bowel perforation, sepsis, and death. For decades, neonatal intensive care units (NICUs) across the country have relied on cow's milk-based formulas manufactured by Abbott Laboratories (Similac) and Mead Johnson (now owned by Reckitt Benckiser, marketing Enfamil) to feed premature infants. A growing body of scientific evidence, however, demonstrates that these cow's milk-based products significantly increase the risk of NEC in preterm neonates compared to exclusive human milk diets.

The NEC baby formula lawsuit represents a rapidly expanding area of mass tort litigation. Families of premature infants who developed necrotizing enterocolitis after being fed Similac or Enfamil products are pursuing claims against these manufacturers, alleging that the companies knew or should have known about the dangers and failed to provide adequate warnings to healthcare providers and parents. For personal injury attorneys seeking to expand their mass tort practice, understanding the science, litigation landscape, and qualification criteria for NEC claims is essential.

NEC baby formula litigation sits at the intersection of product liability, neonatal medicine, and regulatory science — creating a high-value practice area with strong scientific evidence and a sympathetic plaintiff population.

The science behind NEC: how cow's milk-based formula harms premature infants

Why premature infants are uniquely vulnerable

Premature infants, particularly those born before 37 weeks of gestational age, have immature gastrointestinal tracts that lack the protective mechanisms found in full-term neonates. Their intestinal barriers are underdeveloped, mucosal immune systems are not fully functional, and the normal colonization patterns of beneficial gut bacteria have not yet been established. This combination of factors makes the premature infant's digestive system extraordinarily susceptible to injury from foreign proteins and pathogens.

Human breast milk contains immunoglobulins (particularly secretory IgA), lactoferrin, lysozyme, oligosaccharides, and growth factors that protect the immature gut, promote healthy bacterial colonization, and support the development of the intestinal barrier. When premature infants receive cow's milk-based formula instead of human milk, they are deprived of these protective factors and simultaneously exposed to bovine proteins that their immature systems cannot adequately process.

The pathophysiology of formula-induced NEC

The pathophysiology of NEC in formula-fed premature infants involves a cascade of inflammatory events. Cow's milk proteins trigger an abnormal immune response in the immature intestinal mucosa, leading to increased intestinal permeability. This allows bacteria to translocate across the intestinal wall, initiating a severe inflammatory response. The resulting inflammation causes tissue ischemia, necrosis, and in severe cases, full-thickness perforation of the bowel wall.

Research has demonstrated that the osmolality and composition of cow's milk-based formulas, combined with the immature enzymatic activity of the preterm gut, creates an environment conducive to bacterial overgrowth and mucosal injury. Unlike human milk, which has evolved specifically to nourish and protect the developing infant gut, cow's milk formula lacks the bioactive components necessary to maintain intestinal integrity in the vulnerable preterm population.

Key scientific studies linking baby formula to necrotizing enterocolitis

The landmark Cochrane Review

One of the most significant pieces of evidence in NEC baby formula litigation is the Cochrane Systematic Review, which has been updated multiple times and consistently found that formula feeding is associated with a significantly higher incidence of NEC compared to exclusive human milk feeding. The review analyzed data from randomized controlled trials and concluded that feeding premature infants with formula rather than donor human milk substantially increases the risk of NEC.

Sullivan et al. (2010) — the landmark prospective study

The Sullivan et al. study, published in the Journal of Pediatricsin 2010, was a prospective multicenter clinical trial that compared outcomes in extremely premature infants fed an exclusive human milk diet versus those receiving bovine-based products. The study found that infants receiving an exclusive human milk diet had a significantly lower incidence of NEC (surgical NEC rates were reduced by approximately 77%) compared to those receiving any bovine-based products, including cow's milk-based formula and bovine-based human milk fortifiers.

Lucas and Cole (1990) — early evidence of formula risk

The connection between formula feeding and NEC was identified as early as 1990 when Lucas and Cole published their seminal study in The Lancet. This prospective, multicenter study of 926 preterm infants found that NEC was six to ten times more common in exclusively formula-fed infants compared to those fed exclusively with breast milk. This early evidence established the foundation upon which decades of subsequent research have been built.

Additional supporting research

Numerous additional studies have reinforced these findings. Research published in Pediatrics, the Journal of Perinatology, Neonatology, and other peer-reviewed journals has consistently demonstrated that cow's milk-based formula increases NEC risk in premature infants. Meta-analyses combining data from multiple studies have further strengthened the statistical significance of this association, providing a robust evidentiary foundation for litigation.

Abbott Laboratories and Similac: corporate knowledge and failure to warn

Abbott Laboratories, the manufacturer of Similac and Similac Special Care formulas marketed specifically for premature infants, has been a primary defendant in NEC baby formula lawsuits. Plaintiffs allege that Abbott was aware of the scientific literature linking its cow's milk-based products to NEC in premature infants yet continued to aggressively market these products to NICUs and hospitals without adequate warnings about the NEC risk.

Abbott's marketing materials historically emphasized the nutritional benefits of its specialized premature infant formulas while failing to disclose the increased risk of NEC associated with cow's milk-based products. The company maintained relationships with hospitals and healthcare providers, positioning its products as standard of care for premature infant nutrition. Plaintiffs argue that Abbott had a duty to warn healthcare providers and parents about the NEC risk and that its failure to do so constituted negligence and violated product liability standards.

Internal company documents, scientific advisory board communications, and marketing strategy materials are expected to play a significant role in establishing what Abbott knew about the NEC risk and when the company acquired this knowledge. Discovery in these cases has the potential to reveal that Abbott prioritized market share and revenue over infant safety.

Mead Johnson (Reckitt Benckiser) and Enfamil: parallel liability claims

Mead Johnson Nutrition, now a subsidiary of Reckitt Benckiser, manufactures Enfamil and Enfamil Premature formulas. Like Abbott, Mead Johnson faces allegations that it knew or should have known about the risk of NEC in premature infants fed its cow's milk-based products and failed to provide adequate warnings. Enfamil Premature is one of the most commonly used formulas in NICUs across the United States, and its widespread use in the most vulnerable patient population makes the scope of potential liability substantial.

Mead Johnson's marketing practices, including its direct-to-hospital marketing programs, sponsored educational materials, and relationships with neonatologists, are under scrutiny. The company's failure to include NEC warnings on its premature infant formula products despite decades of available scientific evidence forms the core of the negligence and strict liability claims against it.

MDL 3026: the federal NEC baby formula litigation

Formation and consolidation of the MDL

In April 2022, the Judicial Panel on Multidistrict Litigation (JPML) consolidated NEC baby formula lawsuits into MDL No. 3026, titled In Re: Abbott Laboratories, et al., Infant Formula Products Liability Litigation. The MDL was assigned to Judge Rebecca R. Pallmeyer in the United States District Court for the Northern District of Illinois. The consolidation reflected the growing volume of cases filed nationwide and the common questions of fact shared across the litigation.

Case volume and growth trajectory

Since its formation, MDL 3026 has experienced significant and sustained growth in pending cases. As of early 2026, the MDL contains well over a thousand pending cases, with new filings continuing monthly. The growth trajectory of this MDL reflects both the strength of the underlying science and the increasing awareness among attorneys and families about the connection between formula and NEC.

Bellwether trial selection and process

The MDL court has established a bellwether trial selection process to identify representative cases for early trials. Bellwether trials serve as test cases that help both sides evaluate the strengths and weaknesses of their positions and can facilitate global settlement discussions. Early bellwether proceedings have shown promising results for plaintiffs, with initial rulings on key evidentiary issues favoring the admissibility of expert testimony on the causal link between formula and NEC.

Key rulings and procedural developments

Several important rulings in MDL 3026 have shaped the litigation landscape. The court has addressed issues including the admissibility of general causation expert testimony, preemption defenses raised by the manufacturers, and the scope of discovery obligations. Importantly, the court has rejected manufacturer arguments that federal preemption bars state-law failure-to-warn claims, holding that federal regulations do not preempt the duty to provide adequate warnings about known risks.

Clinical presentation and diagnosis of NEC in premature infants

Early signs and symptoms

NEC typically presents in premature infants within the first two to six weeks of life, though onset can occur earlier or later depending on gestational age and feeding history. Early signs include feeding intolerance (increased gastric residuals, emesis), abdominal distension, bloody stools, lethargy, temperature instability, and apneic episodes.

Bell staging criteria

The modified Bell staging criteria classify NEC into three stages based on clinical severity. Stage I (suspected NEC) involves mild systemic signs and mild intestinal findings. Stage II (definite NEC) includes moderate systemic illness, absent bowel sounds, abdominal wall erythema, and radiographic findings including pneumatosis intestinalis. Stage III (advanced NEC) involves severe systemic illness, marked distension, peritonitis, and radiographic evidence of pneumoperitoneum.

Long-term consequences of NEC

Infants who survive NEC often face significant long-term health consequences. Surgical NEC requiring bowel resection can result in short bowel syndrome, a condition requiring prolonged parenteral nutrition and potentially intestinal transplantation. Other long-term sequelae include intestinal strictures, feeding difficulties, growth failure, neurodevelopmental delays, and chronic nutritional deficiencies. The emotional and financial burden on families caring for NEC survivors can be substantial, with lifetime medical costs potentially reaching millions of dollars.

Who qualifies for an NEC baby formula lawsuit: plaintiff screening criteria

Core qualification requirements

To qualify for an NEC baby formula lawsuit, claimants generally must meet the following criteria:

• Premature birth: The infant was born before 37 weeks of gestational age. Very low birth weight (less than 1,500 grams) and extremely premature infants (born before 32 weeks) represent the strongest cases.
• Cow's milk-based formula exposure: The infant was fed a cow's milk-based formula product, such as Similac Special Care, Similac NeoSure, Enfamil Premature, Enfamil NeuroPro EnfaCare, or other bovine-based formulas or fortifiers.
• NEC diagnosis: The infant received a confirmed diagnosis of necrotizing enterocolitis (Bell Stage II or III provides the strongest cases, though Stage I cases may also qualify).
• Temporal relationship: The NEC diagnosis occurred after the introduction of cow's milk-based formula or fortifier into the infant's feeding regimen.

Strongest case profiles

The most compelling NEC cases for litigation typically involve:

• Infants born before 32 weeks gestational age with very low birth weight
• Cases where NEC progressed to Stage II or Stage III requiring surgical intervention
• Cases resulting in bowel resection, ostomy creation, or short bowel syndrome
• Fatal NEC cases where the infant died as a result of the disease or its complications
• Well-documented medical records showing the timeline of formula introduction and NEC onset
• Cases where the infant was receiving primarily or exclusively cow's milk-based formula

Settlement projections and case valuation for NEC claims

While the NEC baby formula MDL has not yet reached a global settlement phase, legal analysts have begun projecting potential settlement values based on comparable mass tort litigation, the severity of injuries involved, and the strength of the scientific evidence.

Building a strong NEC case: strategies for personal injury attorneys

Early case investigation

Building a strong NEC case begins with thorough investigation during the intake process. Attorneys should gather complete NICU medical records, including feeding logs that document every instance of formula administration. Identifying the specific products used (brand name, product line, lot numbers if available) is critical for establishing product identification. Interview parents to understand the feeding decisions made, what information they received from healthcare providers about formula risks, and whether anyone mentioned the possibility of NEC as a risk of formula feeding.

Expert witness development

NEC cases require strong expert testimony in multiple disciplines. Neonatologists can testify about the standard of care for premature infant feeding and how adequate warnings would have changed clinical practice. Epidemiologists and biostatisticians can present the scientific evidence on the causal link between formula and NEC. Pediatric surgeons can explain the surgical interventions required and long-term consequences. Life care planners and economists can quantify future damages for surviving infants with lasting injuries.

Causation analysis

Establishing causation in NEC cases involves demonstrating both general causation (that cow's milk-based formula can cause NEC in premature infants as a general matter) and specific causation (that formula caused NEC in the particular plaintiff's case). General causation is well-supported by the extensive scientific literature. Specific causation requires careful analysis of the individual infant's medical history, gestational age, feeding timeline, and the exclusion of alternative causes.

NEC litigation timeline: key dates and future projections

• 1990: Lucas and Cole publish first major study linking formula to NEC in premature infants.
• 2010: Sullivan et al. study demonstrates exclusive human milk diet reduces surgical NEC by 77%.
• 2011-2021: Multiple additional studies reinforce the formula-NEC link; professional organizations update feeding recommendations.
• 2021-2022: First NEC baby formula lawsuits filed in federal and state courts.
• April 2022: JPML consolidates federal cases into MDL 3026 in the Northern District of Illinois.
• 2023-2024: Discovery phase, expert disclosures, Daubert motions on general causation experts.
• 2024-2025: Bellwether case selection, continued case inventory growth.
• 2026 and beyond: Bellwether trials expected, potential settlement negotiations following trial outcomes.

Cross-referencing related practice areas

NEC baby formula claims are a natural fit for firms already active in pharmaceutical and product liability mass torts. Firms active in this area may also benefit from diversifying into practice areas like hernia mesh, hair relaxer cancer, or Ozempic gastroparesis that provide revenue stability and a broader client base.